The Latest Breaking News from Pfizer

Pfizer Inc. (NYSE:PFE) on Tuesday announced the initial results from a clinical trial called HER2CLIMB-05.  

AstraZeneca joins Pfizer in cutting US drug prices under Trump's new deal to offer lower costs for Medicaid patients.

After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.

UK ministers preparing to raise payments to end standoff with pharma industry, cited as reason for firms axing British investments

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.

Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

Wall Street soared to fresh record highs at the end of the week, brushing aside the 21st U.S. government shutdown in history and a missing jobs report, as investors doubled down on bets for interest rate cuts and cheered strong gains in pharmaceutical and AI-driven tech stocks.